• 1

    Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, 1997. Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 126 :232–236.

    • Search Google Scholar
    • Export Citation
  • 2

    Soto J, Fuya P, Herrera R, Berman J, 1998. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26 :56–58.

    • Search Google Scholar
    • Export Citation
  • 3

    Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL, 1990. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 42 :43–50.

    • Search Google Scholar
    • Export Citation
  • 4

    Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF, 1992. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165 :528–534.

    • Search Google Scholar
    • Export Citation
  • 5

    Romero GA, Guerra MV, Paes MG, Macedo VO, 2001. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65 :456–465.

    • Search Google Scholar
    • Export Citation
  • 6

    Palacios R, Osorio LE, Grajalew LF, Ochoa MT, 2001. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 64 :187–193.

    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 136 51 5
PDF Downloads 25 17 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

SHORT REPORT: EFFICACY OF PENTAVALENT ANTIMONY FOR TREATMENT OF COLOMBIAN CUTANEOUS LEISHMANIASIS

J. SOTOConsorcio de Investigaciones Bioclínicas, Bogota, Colombia; North Bethesda, Maryland

Search for other papers by J. SOTO in
Current site
Google Scholar
PubMed
Close
,
J. TOLEDOConsorcio de Investigaciones Bioclínicas, Bogota, Colombia; North Bethesda, Maryland

Search for other papers by J. TOLEDO in
Current site
Google Scholar
PubMed
Close
,
J. VEGAConsorcio de Investigaciones Bioclínicas, Bogota, Colombia; North Bethesda, Maryland

Search for other papers by J. VEGA in
Current site
Google Scholar
PubMed
Close
, and
J. BERMANConsorcio de Investigaciones Bioclínicas, Bogota, Colombia; North Bethesda, Maryland

Search for other papers by J. BERMAN in
Current site
Google Scholar
PubMed
Close
Restricted access

Two hundred twenty-six consecutive adult patients with cutaneous leishmaniasis in Colombia were treated with Glucantime and 81% were cured. The 19% who failed treatment had received a statistically significant lower total amount of antimony (354 mg/kg) than those who were cured (405 mg/kg) (P = 0.002). Thirty-nine of the failures were re-treated with Glucantime and 59% were cured. This large experience on initial and re-treatment cure rates probably represents the values found in clinical practice. In this series, parasite resistance may have been induced by the relatively low initial dose of antimony administered to some patients.

Author Notes

Reprint requests: J. Soto, Consorcio de Investigaciones Bioclínicas, Calle 60 A 5-54, Suite 201, Bogota, Colombia, Telephone: 57-1-348-2171, Fax: 57-1-347-6093, E-mail: Jaime.Soto@medplus.org.co.
Save